The Thalion Initiative

What The Thalion Initiative does

The Thalion Initiative is a not-for-profit research organization founded in 2024 and headquartered in Boston, with a secondary office in Ottawa. It is dedicated to advancing fundamental aging biology to support development of new therapeutic strategies for age-related diseases. The initiative serves the global scientific research community — academic researchers, institutions, and pharma/biotech — by generating open-access datasets and predictive models, with a stated focus on extending healthspan rather than lifespan alone. Its customer segments are horizontal: scientific researchers (primary), the pharmaceutical/biotech industry, and global healthcare systems.

The initiative operates a portfolio of seven interconnected research programs. Foundational infrastructure includes the P03 Mammalian Biobank (samples from 200+ mammalian species spanning a 200-fold lifespan range) and P16 BAFAR (computational avatars of biological aging for simulation and hypothesis testing). Core research programs cover Embryonic Rejuvenation (multi-omic and bioelectric profiling of the embryonic 'ground zero' rejuvenation event), Comparative Biology (longevity species such as elephants, bowhead whales, axolotls, bats, naked mole rats), Synthetic Biology (JCVI-syn3.0 minimal cells and engineered supra-physiological interventions), Advanced Tooling for Measurement (second-generation SRS microscopy at 14nm resolution, next-gen histone PTM mass spectrometry quantifying 500+ modifications per run, bioelectric profiling, and molecular tracking), and Computational Modeling (machine learning on multi-omics and aging clocks). The execution is organized as a three-phase plan: Phase I foundational research (2025-2033), Phase II translational delivery (2033-2038), and Phase III therapeutic support and licensing (2035-2040).

The Thalion Initiative is funded entirely through philanthropic contributions rather than commercial revenue. Accepted donation channels include Donor Advised Funds (via Fidelity Charitable, DAFgiving360, BNY Mellon), direct cash, gifts-in-kind, cryptocurrency, securities, real estate, life insurance proceeds, retirement plan proceeds, and bequests. A Patron program grants donors access to full research plans, legal/tax documents, and exclusive videos. US nonprofit status is confirmed via EIN 33-2228263 and Candid.org (GuideStar) Gold Seal verification. Leadership comprises Scientific Director Maria Marinova (PhD, Biology of Aging; ex-Apollo Health Ventures; VitaDAO/AthenaDAO contributor), Managing Director Todd White (25 years tech commercialization, 7+ years DeSci angel investing/advisory), and Research Fellow Maximilian Unfried (NUS Centre for Healthy Longevity).

Name

The Thalion Initiative

Legal name

The Thalion Initiative

Website

https://thalion.global

Company type

Private

Founded year

2024

Operating status

Operating

Headcount range

1–10 employees

Short description

The Thalion Initiative is a Boston-based nonprofit research organization (founded 2024) that advances fundamental aging biology through a 200+ species biobank, multi-omics profiling, advanced imaging, and open-access predictive models to inform drug development for the scientific research community.

Ownership category

akta.pro rank

Product category

Aging Biology Research

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Bioinformatics, Multi-Omics Data Analysis & Interpretation Services (HLAGANAI)

akta.pro secondary industries

AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE), In Vivo Discovery & Translational Models Platforms (humanized models, PK/PD, efficacy) (HLAAAIAK), Genomics & Next-Generation Sequencing (NGS) Services (HLAGANAA)

Keywords

• Aging biology research
• Comparative biology studies
• Longevity research programs
• Multi-omics data analysis
• Open science datasets

Headquarters

HQ city

Boston

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales, Others

Revenue model

1. Philanthropic Donations and Charitable Gifts: The Thalion Initiative is a nonprofit organization that accepts donations through multiple channels including Donor Advised Funds (DAF), direct cash donations, gifts-in-kind, cryptocurrency, securities, real estate, and other assets. Donors may direct gifts to specific research programs or provide general support for the initiative.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels4 records

Core offering

The Thalion Initiative is a not-for-profit research organization that conducts a portfolio of interconnected aging biology research programs—including a P03 Mammalian Biobank (samples from 200+ mammalian species) and the P16 BAFAR computational modeling framework—supported by programs in embryonic rejuvenation, comparative biology, synthetic biology, advanced measurement tooling, and computational modeling. These programs generate multi-omics datasets, advanced imaging tools, bioelectric profiling, and predictive models intended to inform drug development and therapeutic interventions for age-related diseases. Outputs, including datasets and tools, are made available on an open-access basis to the scientific research community.

Product overview

The Thalion Initiative is a not-for-profit research organization offering a portfolio of interconnected research programs focused on advancing fundamental aging biology. The core offerings include the P03 Mammalian Biobank (a sample repository of 200+ mammalian species) and P16 BAFAR (computational avatars for aging research), which serve as foundational tools. These are supported by five research initiatives: Embryonic Rejuvenation, Comparative Biology, Synthetic Biology, Advanced Tooling for Measurement, and Computational Modeling. Together, these programs employ first-principles approaches combining comparative biology, synthetic biology, and embryonic rejuvenation to generate high-resolution datasets, develop predictive models, and create advanced measurement tools for therapeutic development.

Differentiator

Problem solved

Functional benefit

Brands

• P03 - Mammalian Biobank: A comprehensive biobank of mammalian species with variation in lifespans, establishing samples from 200+ mammalian species across the phylogenetic tree.
• P16 - BAFAR (Biological Avatars for Aging Research)

Products and services

• P03 - Mammalian Biobank A comprehensive biobank initiative to establish and maintain samples from 200+ mammalian species across the phylogenetic tree, representing a wide range of lifespans, serving as a tool for unraveling the complex biology of aging for the scientific research community.
• P16 - BAFAR (Biological Avatars for Aging Research) Computational modeling framework for biological processes that creates baseline simulation and visualization environments where Thalion and other research project results may be integrated and models developed and refined, providing predictability in translational aging research.
• Embryonic Rejuvenation Research Research program investigating the biological reset that occurs during embryogenesis, exploring mechanisms underlying embryonic rejuvenation and germline maintenance to develop therapeutic strategies for reversing age-related decline, including multi-omic profiling, bioelectric pattern analysis in mouse embryos, iPSCs, and embryoids.
• Comparative Biology Research Research program studying species with unique longevity and disease resistance—including elephants, bowhead whales, axolotls, bats, and naked mole rats—to identify mechanisms relevant to human health and develop innovative therapies, supported by 50 iPSC lines from diverse organisms across mammals, birds, and reptiles.
• Synthetic Biology Research Research program leveraging synthetic biology tools to engineer biological systems and introduce novel molecular capabilities for supra-physiological interventions targeting human aging, using the JCVI-syn3.0 minimal cell as a high-throughput platform for studying fundamental aging processes.
• Advanced Tooling for Measurement Research Research program developing advanced measurement technologies including second-generation super-resolution SRS microscopy (14nm volumetric hyperspectral resolution), bioelectric profiling systems, next-generation mass spectrometry for histone PTMs (quantifying 500+ histone PTMs per experiment), and molecular tracking platforms for high-resolution biological analysis.
• Computational Modeling Research Research program building virtual aging systems, computational avatars of biological aging, and machine learning models to analyze complex datasets and enhance predictability of therapeutic interventions, including a living cell aging biomarker enabling real-time monitoring and closed-loop control of aging-related processes.

Quantifiable outcome

• Addresses the 1.2% FDA approval rate for pre-translational drug candidates by improving predictability in aging biology
• +2 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature8 records

Partnerships

Five partnerships are on record, tiered core and minor.

• J. Craig Venter InstitutecoreStrategic or Co-development PartnerCollaborates with JCVI on synthetic minimal genome cells research using JCVI-syn3.0 for studying fundamental aging processes. JCVI scientists Tae Seok Moon (Professor) and John Glass (Professor and Director of JCVI La Jolla campus) serve on The Thalion Initiative's Scientific Advisory Board for Synthetic Biology.
• Bat1K ConsortiumcoreStrategic or Co-development PartnerThe Thalion Initiative's Scientific Advisory Board member Emma Teeling (UCD) is a Founding Director of the Bat1K genome consortium, which aims to sequence the genomes of all bat species. This supports the comparative biology research program focused on understanding longevity mechanisms in bats.
• VitaDAOminorStrategic or Co-development PartnerScientific Director Maria Marinova has been an active participant in the decentralized science movement through VitaDAO, blending scientific expertise with tech transfer and blockchain-enabled tools. This connection supports the initiative's engagement with the DeSci community.
• AthenaDAOminorStrategic or Co-development PartnerScientific Director Maria Marinova has been an active participant in the decentralized science movement through AthenaDAO, contributing to the initiative's engagement with the DeSci community around aging biology.
• National University Singapore (NUS) Centre for Healthy LongevitycoreStrategic or Co-development PartnerResearch Fellow Maximilian Unfried holds a position at the Centre for Healthy Longevity at NUS. Advisory board member Brian Kennedy serves as Director of the Healthy Longevity Translational Research Programme at NUS. Advisory board member Jan Gruber joined NUS in 2023 as part of the Healthy Longevity Translational Research Programme.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Altos Labs: Well-capitalized ($3B+ raised) biotechnology company pursuing cellular rejuvenation programming to treat age-related diseases. Comparable because it targets the same biological reset mechanisms (including embryonic-style rejuvenation) that Thalion studies in P03/P-embryogenesis, but operates a closed R&D model with commercial therapeutic ambitions.
• Calico Labs: Alphabet-backed longevity research company focused on fundamental biology of aging and translational development of interventions. A broad incumbent peer because it pursues the same first-principles aging biology mission with vastly more capital (estimated $1B+ commitment fromAlphabet). The key difference is the closed, proprietary model versus Thalion's open-access approach.
• Mayo Clinic Kogod Center on Aging: Major academic research center within the Mayo Clinic focused on understanding the biology of aging and translating findings into clinical interventions. Comparable as a multi-omics, aging-biology research organization, but embedded within a hospital system rather than an independent nonprofit.

Emerging players

• NewLimit: Biotechnology company using epigenetic reprogramming to treat age-related disease. Partial overlap with Thalion's embryonic rejuvenation research and BAFAR computational modeling, but operates as a commercial therapeutics company with a narrower mechanistic focus (Yamanaka factors).
• Life Biosciences: Biotechnology company developing therapeutics that target the biology of aging across multiple indications. Comparable in its aging-focused mission and application of multi-omics, but operates as a for-profit with parallel partiality to gene therapy and cellular reprogramming.
• Insilico Medicine: AI-driven drug discovery company with a dedicated longevity and aging therapeutics pipeline. Comparable because of its emphasis on AI/ML-enabled biology, multi-omics analysis, and aging biomarker development. Distinct in being a commercial enterprise with a drug pipeline rather than a discovery research platform.

Direct peers

• SENS Research Foundation: Nonprofit research foundation focused on the fundamental biology of aging and rejuvenation biotechnologies. It is the most structurally and philosophically comparable peer to Thalion: both operate as nonprofits, both pursue open-science approaches to aging-related damage repair, and both target translational outcomes for age-related disease. Distinguished by SENS's longer operating history (founded 2009) and damage-repair orientation, whereas Thalion emphasizes comparative biology and computational modeling.
• Longevity Science Foundation: Nonprofit funding research and projects aimed at extending healthy human lifespan. Comparable as a longevity-focused nonprofit, though it operates more as a grant-making entity than a primary research organization, distinguishing it from Thalion's direct research model.
• Buck Institute for Research on Aging: Independent nonprofit biomedical research institute dedicated solely to aging research. Direct peer because it operates a similar nonprofit research model, pursues aging biology at the molecular and cellular level, and leverages multi-omics and computational approaches. Distinction: Buck is much larger (~230 employees, ~$80M+ budget), affiliated with a major campus, and has a longer publication track record.

Others

• VitaDAO: Decentralized autonomous organization funding early-stage longevity research. Comparable because Thalion's Scientific Director actively participates in VitaDAO and shares the DeSci community lens. Distinction: VitaDAO is a funding mechanism rather than a research organization, making it an ecosystem peer rather than a direct competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/TTIScience
• YouTubeyoutube.com/@TTIScience
• LinkedInlinkedin.com/company/the-thalion-initiative

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about The Thalion Initiative